Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekt av HIgh-flow terapi i langsiktig oksygenterapi (HILOT)

16. november 2026 oppdatert av: Magnus Ekström, Skane University Hospital

Effekt av HIgh-flow terapi i langsiktig oksygenterapi (HILOT): En multisenter, registerbasert, randomisert klinisk studie

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.

The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.

Studietype

Intervensjonell

Registrering (Antatt)

310

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Örebro, Sverige, 70185
        • Rekruttering
        • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
        • Ta kontakt med:
          • Josefin Sundh, MD, PhD
    • Blekinge County
      • Karlskrona, Blekinge County, Sverige, 37185
        • Rekruttering
        • Research Unit, Blekinge University of Technology
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 40 years or older
  • Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
  • COPD or ILD as main underlying reason for LTOT
  • Oxygen concentrator as stationary oxygen source in the home including night-time
  • Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

  • Current or previous treatment with home HFOT
  • Current treatment with home mechanical ventilation
  • Current treatment with home CPAP
  • Hospitalized during the last 2 weeks
  • Current smoking or contact with flames
  • Self-reported average use of the LTOT < 15h per day (24 hours)
  • PaCO2 (breathing air at rest) > 8 kPa
  • Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
  • Inability to participate in the study procedures (as judged by the staff)
  • Not eligible for continuing LTOT due to other reason (as judged by the staff)
  • Expected survival less than 3 months (as judged by the staff)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: High-flow oxygen therapy

Intervention arm

Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

Aktiv komparator: Low-flow oxygen therapy

Comparison arm

Standard care with low-flow oxygen therapy in accordance with clinical routine.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to first hospitalization or death from all causes
Tidsramme: 1 year

Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)

1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to first all-cause hospitalization or all-cause death
Tidsramme: 1 year

Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)

1 year
Rate of hospitalizations or death from all causes
Tidsramme: 1 year

Rate of hospitalizations or death from all causes assessed using nationwide registry data

1 year
Hospitalization rate from all causes
Tidsramme: 1 year

Hospitalization rate from all causes assessed using nationwide registry data

1 year
Hospitalization rate from respiratory disease
Tidsramme: 1 year

Hospitalization rate from respiratory disease assessed using nationwide registry data

1 year
Number of hospitalized days
Tidsramme: 1 year

Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data

1 year
Hospitalization rate from cardiovascular disease
Tidsramme: 1 year

Hospitalization rate from cardiovascular disease assessed using nationwide registry data

1 year
Number of admissions to intensive care unit (ICU)
Tidsramme: 1 year

Number of admissions to ICU assessed using nationwide registry data

1 year
Number of days in ICU
Tidsramme: 1 year

Number of days in ICU assessed using nationwide registry data

1 year
Mortality rate from all causes
Tidsramme: 1 year

The mortality rate from all causes assessed using nationwide registry data

1 year
Mortality rate from respiratory disease
Tidsramme: 1 year

The mortality rate from respiratory disease assessed using nationwide registry data

1 year
Mortality rate from cardiovascular disease
Tidsramme: 1 year

The mortality rate from cardiovascular disease assessed using nationwide registry data

1 year
Time to first exacerbation
Tidsramme: 1 year

Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data

1 year
Number of exacerbations
Tidsramme: 1 year

Number of exacerbations of all severity assessed using self-reported and registry data

1 year
Incidence of cardiovascular disease
Tidsramme: 1 year

Incidence of cardiovascular disease assessed using nationwide registry data

1 year
Need for home mechanical ventilation
Tidsramme: 1 year

Need for starting home mechanical ventilation assessed using nationwide registry data

1 year
Rate of withdrawal of long-term oxygen therapy
Tidsramme: 1 year

Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data

1 year
Adverse events
Tidsramme: 3 and 12 months

Self-reported adverse events since study start assessed using a postal questionnaire.

3 and 12 months
Primary care utilization
Tidsramme: 1 year

Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.

1 year
Health-related quality of life
Tidsramme: 3 and 12 months

Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.

3 and 12 months
Health status
Tidsramme: 3 and 12 months

Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.

3 and 12 months
Breathlessness at exertion
Tidsramme: 3 and 12 months

Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.

3 and 12 months
Breathlessness
Tidsramme: 3 and 12 months

Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.

3 and 12 months
Sleep quality
Tidsramme: 3 and 12 months

Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.

3 and 12 months
Physical activity
Tidsramme: 3 and 12 months

Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.

3 and 12 months
Change in health status
Tidsramme: 3 and 12 months

Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.

3 and 12 months
Nasal symptoms
Tidsramme: 3 and 12 months

Self-reported nasal symptoms assessed using the modified Björklund questionnaire.

3 and 12 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient preference for continuing the treatment
Tidsramme: 3 and 12 months

Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.

3 and 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Magnus Ekström, MD, PhD, Skane University Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. juni 2024

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

17. januar 2024

Først innsendt som oppfylte QC-kriteriene

6. februar 2024

Først lagt ut (Faktiske)

7. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HILOT

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .